Bristol-Myers Squibb Company (NYSE: BMY), announced that Elliott Sigal, M.D., Ph.D., has been elected to its Board of Directors, effective today. Dr. Sigal will also be a member of the Board’s Science and Technology Committee.
Dr. Sigal reports to Lamberto Andreotti, chief executive officer, as executive vice president, chief scientific officer and president, Bristol-Myers Squibb Research and Development, a position he has held since 2004.
Dr. Sigal joined Bristol-Myers Squibb in November 1997 as vice president of Applied Genomics. Since then he has served in critical leadership roles within R&D, including drug discovery and development.
“We are very excited to have Elliott join our Board,” said James M. Cornelius, chairman, Bristol-Myers Squibb. “Under his leadership, our R&D organization has become one of the most productive in the industry. Today’s appointment recognizes his great contribution to the company.”
“Elliott’s election to our Board recognizes the importance of R&D to our strategy and our success as a BioPharma company,” added Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “Elliott is an important member of my Senior Management Team, a team that joins me in congratulating him on this great honor and his many accomplishments.”
The shares of Bristol-Myers are trading at $25.67, down 0.54 percent.
